Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

ASCO GI 2021: MRD Detection With ctDNA From Assays

February 22nd 2021

Expert physicians discuss data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium) 2021 annual meeting, regarding minimal residual disease (MRD) detection with ctDNA (circulating tumor DNA) from personalized assays in stage II and III patients with colorectal cancer.

ASCO GI 2021: Circulating Tumor DNA Analysis Data

February 22nd 2021

An overview of data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal) 2021 Annual Meeting, regarding the circulating tumor DNA for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment of patients with colorectal cancer (CRC).

ctDNA Monitorization Length and Clinical Experience

February 22nd 2021

Experts in the management of colorectal cancer (CRC) consider how long patients with early stage disease should receive ctDNA (circulating tumor DNA) monitorization, and provide insight into their personal experience using ctDNA testing.

Cologuard mt-sDNA Test Could Provide a Noninvasive Screening Option for CRC

February 19th 2021

February 19, 2021 - Multitarget stool DNA test Cologuard could present a potential noninvasive screening method for colorectal cancer, as it has demonstrated high specificity among average-risk patients aged 45 to 49 years.

Dr. Dasari on the Rationale for the FRESCO-2 Trial With Fruquintinib in mCRC

February 19th 2021

Nageshwara Arvind Dasari, MD, discusses the rationale to evaluate fruquintinib in the ongoing, phase 3 FRESCO-2 trial in patients with metastatic colorectal cancer.

Dr. Wainberg on the Need for Chemotherapy-Free Options in CRC

February 18th 2021

Zev A. Wainberg, MD, discusses the need to develop chemotherapy-free options in colorectal cancer.

Dr. Ciombor on the Efficacy of Preoperative Chemoradiation in Rectal Cancer

February 17th 2021

Kristen K. Ciombor, MD, MSCI, discusses responses achieved with preoperative chemoradiation in patients with rectal cancer.

Dr. Grothey on the Rationale to Evaluate Patritumab Deruxtecan in HER3+ CRC

February 16th 2021

Axel Grothey, MD, discusses the rationale to evaluate patritumab deruxtecan in HER3-positive colorectal cancer.

Dr. Raghav on the Utility of Chemotherapy-Free Intervals in CRC

February 15th 2021

Kanwal Raghav, MBBS, MD, discusses the utility of chemotherapy-free intervals in colorectal cancer.

ctDNA-Guided MRD Assessment Enters New Horizon in Colon Cancer

February 15th 2021

Finding a reliable biomarker for minimal residual disease assessment is needed and circulating tumor DNA has shown incredible promise in colon cancer.

Role of ctDNA Testing/Monitoring in Early-Stage CRC

February 15th 2021

A discussion on the evolving role of ctDNA (circulating tumor DNA) testing and monitoring in early-stage colorectal cancer (CRC).

Treatment Approach for Stage II/III Resectable CRC

February 15th 2021

Key opinion leaders discuss their approach for the treatment of patients with stage II/III resectable colorectal cancer (CRC), with special consideration of factors for choosing perioperative therapy and the management of low- vs high-risk patients.

Dr. Coveler on the Rationale to Evaluate NUC-3373 in Metastatic CRC

February 12th 2021

Andrew Coveler, MD, discusses the rationale to evaluate NUC-3373 in metastatic colorectal cancer.

Dr. Ciombor on Ongoing Research Efforts in Rectal Cancer

February 11th 2021

Kristen K. Ciombor, MD, MSCI, discusses ongoing research efforts being made in rectal cancer.

Grothey Spotlights Personalized Approaches Shaking Up CRC Care Continuum

February 10th 2021

Axel Grothey, MD, highlights recent advancements in CRC treatment, including innovative combinations and emerging agents that are generating excitement in the field.

Open Questions and Future Directions in mCRC

February 4th 2021

Experts in CRC discuss questions and management of mCRC.

Using Molecular Testing to Guide Treatment Selection in mCRC

February 4th 2021

John Marshall, MD, and Axel Grothey, MD, discuss how molecular testing results guide treatment decisions in patients with mCRC.

Drive-By Flu-FIT Program May Address CRC Screening Decline in Diverse Communities Amidst COVID-19 Crisis

February 3rd 2021

February 3, 2021 - The Drive-By Flu-Fecal Immunochemical Test program not only provides safe and socially distanced colorectal cancer screening opportunities during the coronavirus disease 2019 pandemic, but also may help to address screening declines in diverse communities.

ASCO Names Molecular Profiling in GI Cancers as Advance of the Year

February 2nd 2021

February 2, 2021 - ASCO has chosen molecular profiling driving progress in gastointestinal cancers as its Advance of the Year.

Dr. Ciombor on Sequencing Therapies in Locally Advanced Rectal Cancer

February 2nd 2021

Kristen K. Ciombor, MD, MSCI, discusses sequencing treatment options for patients with locally advanced rectal cancer.